Skip to main content
. Author manuscript; available in PMC: 2015 Jun 14.
Published in final edited form as: Pharm Pat Anal. 2014 May;3(3):261–277. doi: 10.4155/ppa.14.18

Figure 2. The published patents related to multiple myeloma treatments and their associated targets.

Figure 2

APRIL: A proliferation-inducing ligand; BMSC: Bone marrow stromal cells; CB2: Cannabinoid receptor 2; CD40: TNF receptor superfamily member 5; CXCR4: Chemokine receptor type 4; DKK1: Dickkopf-related protein 1; ERK: Extracellular signal-regulated kinases; FGFR3: Fibroblast growth factor receptor 3; HGF: Hepatocyte growth factor; Hsp90: Heat shock protein 90; JAK: Janus kinase; MAPK: Mitogen-activated protein kinase; MEK: Mitogen-activated protein kinase kinase; MIP-1α: Macrophage inflammatory protein-1α; MM cell: Multiple myeloma cell; mTOR: Mammalian target of rapamycin; PI3K: Phosphatidylinositide 3-kinases; PPARγ: Peroxisome proliferator-activated receptor gamma; PTEN: Phosphatase and tensin homolog; SDF-1α: Stromal cell-derived factor 1; STAT3: Signal transducer and activator of transcription 3; UPR: Unfolded protein response; VCAM: Vascular cell adhesion protein 1; VLA4: Very late antigen-4.